These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Examination of the effects of financial risk on the formal treatment costs for a Medicaid population with psychiatric disabilities. Jones K; Chen HJ; Jordan N; Boothroyd RA; Ramoni-Perazzi J; Shern DL Med Care; 2006 Apr; 44(4):320-7. PubMed ID: 16565632 [TBL] [Abstract][Full Text] [Related]
5. Medication restrictions: feeling the side effects. Fitzpatrick C Behav Healthc Tomorrow; 2001 Oct; 10(5):14-7, 39-40. PubMed ID: 11594068 [No Abstract] [Full Text] [Related]
6. States' control of prescription drug spending: a heterogeneous approach. Morden NE; Sullivan SD Health Aff (Millwood); 2005; 24(4):1032-8. PubMed ID: 16012143 [TBL] [Abstract][Full Text] [Related]
7. New York Medicaid: never can say goodbye. Fastiggi J Cornell J Law Public Policy; 2007; 16(3):581-615. PubMed ID: 18521998 [No Abstract] [Full Text] [Related]
8. Trends in mental health cost growth: an expanded role for management? Frank RG; Goldman HH; McGuire TG Health Aff (Millwood); 2009; 28(3):649-59. PubMed ID: 19414870 [TBL] [Abstract][Full Text] [Related]
10. Using clinical evidence to manage pharmacy benefits: experiences of six states. Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357 [TBL] [Abstract][Full Text] [Related]
11. Reduced drug coverage saved Medicaid 'pennies,' cost state 'pounds'. Am J Hosp Pharm; 1994 Nov; 51(21):2622. PubMed ID: 7856574 [No Abstract] [Full Text] [Related]
12. Medicaid managed care and the distribution of societal costs for persons with severe mental illness. Shern DL; Jones K; Chen HJ; Jordan N; Ramoni-Perazzi J; Boothroyd RA Am J Psychiatry; 2008 Feb; 165(2):254-60. PubMed ID: 18198269 [TBL] [Abstract][Full Text] [Related]
13. Need for therapeutic guidelines for antipsychotics under a prescription cap. Sutherland LG Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S19-22. PubMed ID: 9872690 [No Abstract] [Full Text] [Related]
14. Prescription drug benefits under Part D of the Medicare Modernization Act--the genie's out of the bottle. Andersen LS Issue Brief Cent Medicare Educ; 2005; 5(10):1-10. PubMed ID: 15943013 [TBL] [Abstract][Full Text] [Related]
15. Commentary: purchasing community perspective. Moore MC J Clin Psychiatry; 2003; 64 Suppl 17():33-4. PubMed ID: 14680426 [No Abstract] [Full Text] [Related]
16. Restrictive formularies counterbalanced by higher admissions, medical costs. Anderson J Rep Med Guidel Outcomes Res; 2000 Jan; 11(2):8-10. PubMed ID: 11768404 [No Abstract] [Full Text] [Related]
17. The ripple effects of a restrictive Medicaid formulary. Grabowski H Am J Manag Care; 2003 Oct; 9(10):648-9. PubMed ID: 14572174 [No Abstract] [Full Text] [Related]
18. Commentary: health care organization perspective. Goldman W J Clin Psychiatry; 2003; 64 Suppl 17():35-6. PubMed ID: 14680427 [No Abstract] [Full Text] [Related]
19. Changes in Medicaid prescription volume and use in the wake of Medicare Part D implementation. Bruen BK; Miller LM Health Aff (Millwood); 2008; 27(1):196-202. PubMed ID: 18180495 [TBL] [Abstract][Full Text] [Related]